Annual Accounts Payable
$108.90 M
+$41.60 M+61.81%
31 December 2023
Summary:
Neurocrine Biosciences annual accounts payable is currently $108.90 million, with the most recent change of +$41.60 million (+61.81%) on 31 December 2023. During the last 3 years, it has risen by +$57.40 million (+111.46%). NBIX annual accounts payable is now at all-time high.NBIX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$95.70 M
-$11.50 M-10.73%
30 September 2024
Summary:
Neurocrine Biosciences quarterly accounts payable is currently $95.70 million, with the most recent change of -$11.50 million (-10.73%) on 30 September 2024. Over the past year, it has dropped by -$13.20 million (-12.12%). NBIX quarterly accounts payable is now -12.12% below its all-time high of $108.90 million, reached on 31 December 2023.NBIX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -12.1% |
| 3 y3 years | +111.5% | +85.8% |
| 5 y5 years | +163.0% | +131.2% |
NBIX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +111.5% | -12.1% | +85.8% |
| 5 y | 5 years | at high | +176.4% | -12.1% | +142.9% |
| alltime | all time | at high | >+9999.0% | -12.1% | >+9999.0% |
Neurocrine Biosciences Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $95.70 M(-10.7%) |
| June 2024 | - | $107.20 M(+22.8%) |
| Mar 2024 | - | $87.30 M(-19.8%) |
| Dec 2023 | $108.90 M(+61.8%) | $108.90 M(+16.1%) |
| Sept 2023 | - | $93.80 M(+39.4%) |
| Dec 2022 | $67.30 M(+30.7%) | $67.30 M(+30.7%) |
| Dec 2021 | $51.50 M(+30.7%) | $51.50 M(+30.7%) |
| Dec 2020 | $39.40 M(-4.8%) | $39.40 M(-4.8%) |
| Dec 2019 | $41.40 M(+7.9%) | $41.40 M(+7.9%) |
| Dec 2018 | $38.38 M(+579.6%) | $38.38 M(+579.6%) |
| Dec 2017 | $5.65 M(+11.1%) | $5.65 M(+562.9%) |
| Mar 2017 | - | $852.00 K(-83.2%) |
| Dec 2016 | $5.08 M(+98.6%) | $5.08 M(+195.8%) |
| Sept 2016 | - | $1.72 M(-2.4%) |
| June 2016 | - | $1.76 M(-17.0%) |
| Mar 2016 | - | $2.12 M(-17.1%) |
| Dec 2015 | $2.56 M(+941.1%) | $2.56 M(+114.0%) |
| Sept 2015 | - | $1.20 M(+15.7%) |
| June 2015 | - | $1.03 M(-18.5%) |
| Mar 2015 | - | $1.27 M(+416.3%) |
| Dec 2014 | $246.00 K(+143.6%) | $246.00 K(-72.7%) |
| Sept 2014 | - | $900.00 K(+6.4%) |
| June 2014 | - | $846.00 K(+3.4%) |
| Mar 2014 | - | $818.00 K(+709.9%) |
| Dec 2013 | $101.00 K(-88.9%) | $101.00 K(-90.8%) |
| Sept 2013 | - | $1.10 M(-18.6%) |
| June 2013 | - | $1.35 M(-7.7%) |
| Mar 2013 | - | $1.46 M(+60.3%) |
| Dec 2012 | $911.00 K(-18.0%) | $911.00 K(-35.7%) |
| Sept 2012 | - | $1.42 M(-0.3%) |
| June 2012 | - | $1.42 M(+138.3%) |
| Mar 2012 | - | $596.00 K(-46.4%) |
| Dec 2011 | $1.11 M(+37.2%) | $1.11 M(+45.0%) |
| Sept 2011 | - | $766.00 K(-17.8%) |
| June 2011 | - | $932.00 K(+83.8%) |
| Mar 2011 | - | $507.00 K(-37.4%) |
| Dec 2010 | $810.00 K(-63.0%) | $810.00 K(-11.2%) |
| Sept 2010 | - | $912.00 K(+42.5%) |
| June 2010 | - | $640.00 K(+18.7%) |
| Mar 2010 | - | $539.00 K(-75.4%) |
| Dec 2009 | $2.19 M(+36.8%) | $2.19 M(+45.8%) |
| Sept 2009 | - | $1.50 M(-14.3%) |
| June 2009 | - | $1.75 M(-31.3%) |
| Mar 2009 | - | $2.55 M(+59.5%) |
| Dec 2008 | $1.60 M(-57.7%) | $1.60 M(-46.5%) |
| Sept 2008 | - | $2.99 M(+9.1%) |
| June 2008 | - | $2.74 M(+94.5%) |
| Mar 2008 | - | $1.41 M(-62.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $3.78 M(+17.5%) | $3.78 M(-78.2%) |
| Sept 2007 | - | $17.29 M(+10.4%) |
| June 2007 | - | $15.66 M(+12.6%) |
| Mar 2007 | - | $13.91 M(+332.9%) |
| Dec 2006 | $3.21 M(-84.9%) | $3.21 M(-79.2%) |
| Sept 2006 | - | $15.43 M(-10.5%) |
| June 2006 | - | $17.23 M(+2.6%) |
| Mar 2006 | - | $16.79 M(-21.3%) |
| Dec 2005 | $21.34 M(+295.9%) | $21.34 M(+18.0%) |
| Sept 2005 | - | $18.09 M(+2.1%) |
| June 2005 | - | $17.72 M(-5.4%) |
| Mar 2005 | - | $18.73 M(+247.5%) |
| Dec 2004 | $5.39 M(+316.3%) | $5.39 M(-81.8%) |
| Sept 2004 | - | $29.57 M(+9.0%) |
| June 2004 | - | $27.12 M(+831.9%) |
| Mar 2004 | - | $2.91 M(+124.7%) |
| Dec 2003 | $1.29 M(-33.9%) | $1.29 M(-32.3%) |
| Sept 2003 | - | $1.91 M(-29.6%) |
| June 2003 | - | $2.72 M(+25.6%) |
| Mar 2003 | - | $2.16 M(+10.4%) |
| Dec 2002 | $1.96 M(+27.3%) | $1.96 M(-46.6%) |
| Sept 2002 | - | $3.67 M(+153.9%) |
| June 2002 | - | $1.45 M(+66.5%) |
| Mar 2002 | - | $868.00 K(-43.6%) |
| Dec 2001 | $1.54 M(+44.5%) | $1.54 M(+13.7%) |
| Sept 2001 | - | $1.35 M(+85.2%) |
| June 2001 | - | $731.00 K(+11.1%) |
| Mar 2001 | - | $658.00 K(-38.2%) |
| Dec 2000 | $1.06 M(-55.6%) | $1.06 M(+36.0%) |
| Sept 2000 | - | $783.00 K(+11.9%) |
| June 2000 | - | $700.00 K(-59.8%) |
| Mar 2000 | - | $1.74 M(-27.5%) |
| Dec 1999 | $2.40 M(-4.0%) | $2.40 M(+200.0%) |
| Sept 1999 | - | $800.00 K(-33.3%) |
| June 1999 | - | $1.20 M(+71.4%) |
| Mar 1999 | - | $700.00 K(-72.0%) |
| Dec 1998 | $2.50 M(+38.9%) | $2.50 M(+127.3%) |
| Sept 1998 | - | $1.10 M(+83.3%) |
| June 1998 | - | $600.00 K(+20.0%) |
| Mar 1998 | - | $500.00 K(-72.2%) |
| Dec 1997 | $1.80 M(+125.0%) | $1.80 M(+5.9%) |
| Sept 1997 | - | $1.70 M(+240.0%) |
| June 1997 | - | $500.00 K(-44.4%) |
| Mar 1997 | - | $900.00 K(+12.5%) |
| Dec 1996 | $800.00 K | $800.00 K(+33.3%) |
| Sept 1996 | - | $600.00 K(-45.5%) |
| June 1996 | - | $1.10 M(+450.0%) |
| Mar 1996 | - | $200.00 K |
FAQ
- What is Neurocrine Biosciences annual accounts payable?
- What is the all time high annual accounts payable for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly accounts payable?
- What is the all time high quarterly accounts payable for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly accounts payable year-on-year change?
What is Neurocrine Biosciences annual accounts payable?
The current annual accounts payable of NBIX is $108.90 M
What is the all time high annual accounts payable for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual accounts payable is $108.90 M
What is Neurocrine Biosciences quarterly accounts payable?
The current quarterly accounts payable of NBIX is $95.70 M
What is the all time high quarterly accounts payable for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly accounts payable is $108.90 M
What is Neurocrine Biosciences quarterly accounts payable year-on-year change?
Over the past year, NBIX quarterly accounts payable has changed by -$13.20 M (-12.12%)